Search Within

Erel Joffe

Formats
  1. Meeting Abstract (56)
  2. Journal Article (23)
  3. Research Letter (3)
  4. Review (2)
Groups
  1. Department of Medicine (84)
  2. Hematologic Malignancies, Division of (84)
  3. Sloan Kettering Institute Postdocs (84)
  4. Survivorship Research (56)
  5. Center for Hematologic Malignancies (50)
  6. Lymphoma (49)

More Groups

People
  1. Andrew Zelenetz (46)
  2. Ariela Noy (41)
  3. Maria Palomba (41)
  4. Matthew Matasar (38)
  5. Connie Batlevi (36)
  6. Paul Hamlin (36)

More People

Years
  1. 2024 (5)
  2. 2023 (9)
  3. 2022 (14)
  4. 2021 (22)
  5. 2020 (18)
  6. 2019 (13)

More Years

Publications
  1. Blood (31)
  2. Hematological Oncology (10)
  3. Journal of Clinical Oncology (9)
  4. Blood Advances (6)
  5. Blood Cancer Journal (4)
  6. International Journal of Radiation Oncology, Biology, Physics (3)

More Publications

Publishers
  1. American Society of Hematology (37)
  2. Wiley Blackwell (10)
  3. American Society of Clinical Oncology (9)
  4. Elsevier Inc. (8)
  5. Nature Publishing Group (5)
  6. Taylor & Francis Group (3)

More Publishers

Results (84)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P. A.; Kim, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Joffe, E.; Nowakowski, G. S.; Tun, H. W.; Rosenthal, A. C.; Lunning, M. A.; Ramchandren, R.; Li, C. C.; Zhou, L.; Martinez, E.; Von Roemeling, R. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study
    Journal Article

    Nowakowski, G. S.; Yoon, D. H.; Peters, A.; Mondello, P.; Joffe, E.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Meeting Abstract

    Freret, M.; Imber, B.; Joffe, E.; Yahalom, J.; Hajj, C.
    Radiotherapy and Oncology (2022)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Applying LymphGen classification to a clinically validated 400-gene targeted next-generation sequencing (NGS) panel in diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Zhu, M.; Drill, E.; Joffe, E.; Arcila, M.; Dogan, A.
    Modern Pathology (2022)

    Fulltext@MSK | Save
  • Applying lymphgen classification to a clinically validated 400-gene targeted next-generation sequencing (NGS) panel in diffuse large b-cell lymphoma (DLBCL)
    Meeting Abstract

    Zhu, M.; Drill, E.; Joffe, E.; Arcila, M.; Dogan, A.
    Laboratory Investigation (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save